NCT01902173 2025-01-14Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV CancerNational Cancer Institute (NCI)Phase 1/2 Completed27 enrolled 16 charts
NCT00920140 2014-04-02Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory LeukemiasGlaxoSmithKlinePhase 2 Completed97 enrolled 23 charts